GlassScriptPhysician profile
Amrita Rampertaap
NPI 1750915203
$3,297.59
in general payments reported to CMS, 2019-2025
24 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,055 · 2022: $824 · 2023: $760 · 2024: $183 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406 · Entertainment: $12.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.31 |
| Entertainment | $12.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,056.51 | 2021-2025 | |
| Novo Nordisk INC | $714.28 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $363.91 | 2021-2025 | Mounjaro, Reyvow, Emgality |
| Pfizer INC. | $328.96 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.45 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $93.65 | 2022-2025 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $77.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $73.76 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $63.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.62 | 2021 | |
| Irhythm Technologies, INC. | $42.33 | 2023 | Zio Xt Patch |
| Exact Sciences Corporation | $38.04 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $33.93 | 2022-2024 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $33.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.64 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.56 | 2023 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $26.72 | 2021 | |
| Ibsa Pharma INC. | $24.07 | 2021 | |
| Merz North America, INC. | $22.56 | 2021 | |
| Glaxosmithkline, LLC. | $22.48 | 2023 | Trelegy Ellipta |
| Neurelis, INC. | $21.06 | 2025 | Valtoco |
| Esperion Therapeutics, INC. | $18.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.17 | 2022 | |
| Optos, INC. | $12.90 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrita Rampertaap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.